Semaglutide
A long-acting GLP-1 receptor agonist with extensive metabolic clinical-trial literature.
Overview
Semaglutide is a GLP-1 receptor agonist and one of the most extensively studied incretin compounds, with a deep base of published clinical research in glucose regulation and body weight.
How it’s studied to work
It activates the GLP-1 receptor, studied for effects on glucose-dependent insulin secretion, gastric emptying, and central appetite signalling.
Research areas
- ›Glucose-regulation research
- ›Appetite and body-weight studies
- ›Cardiometabolic endpoints
Further reading
Links open external literature databases. Citations are curated starting points, not an exhaustive or endorsing list.
For laboratory and research use only. Not a drug, supplement, or medical device. This page is educational and is not medical advice; nothing here describes a product intended for human or veterinary use.